<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Flecainide is a class Ic antiarrhythmic agent available in Europe since 1982 </plain></SENT>
<SENT sid="1" pm="."><plain>The clinical development program of flecainide provided good data on its antiarrhythmic effect for the prevention of ventricular and <z:hpo ids='HP_0005115'>supraventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:hpo ids='HP_0011675'>Cardiac Arrhythmia</z:hpo> Suppression Trial (CAST), conducted to test whether the <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> suppression translates into prevention of <z:hpo ids='HP_0001699'>sudden death</z:hpo>, assessed the impact of flecainide and encainide therapy in patients with frequent ventricular ectopics and reduced left ventricular function who had survived an infarction </plain></SENT>
<SENT sid="3" pm="."><plain>In that population, flecainide and encainide increased mortality </plain></SENT>
<SENT sid="4" pm="."><plain>Consequently, <z:chebi fb="199" ids="26708">sodium</z:chebi> channel blockers are now rarely used to prevent <z:hpo ids='HP_0001699'>sudden death</z:hpo> and are not recommended in patients with <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Current European and North American guidelines recommend the use of flecainide in carefully selected patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) and no documented structural <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>AREAS COVERED: The aim of this review is to evaluate the available data on efficacy and safety of flecainide in <z:hpo ids='HP_0000001'>all</z:hpo> the spectrum of its indications including cardioversion of recent-<z:hpo ids='HP_0003674'>onset</z:hpo> AF, sinus rhythm maintenance in paroxysmal AF and management of ventricular tachyarrhythmias </plain></SENT>
<SENT sid="7" pm="."><plain>EXPERT OPINION: In the setting of AF and in carefully selected patients without structural <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e>, flecainide has shown a good efficacy and safety for both cardioversion and sinus rhythm maintenance </plain></SENT>
</text></document>